ClinicalTrials.gg
Status unknownNCT01264237Updated Mar 23, 2011

Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain

A Phase 4 interventional study of Etoricoxib and Placebo in Postherpetic Neuralgia and Neuralgia, sponsored by Analgesic Solutions. Status unknown at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-23.

Sponsored by Analgesic Solutions · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2011), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Neuralgia, Postherpetic with a site in United Kingdom — none open to participants now, none under way, none of them phase 3. Neuralgia, Postherpetic · United Kingdom.

Planned enrollment
8th of 12
120 · median 131
Started
2011
the only one that year
Phase 4
4 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
Analgesic Solutions

Among the 12 studies in Neuralgia, Postherpetic with a site in United Kingdom, this one is the 8th largest by planned enrollment, is the only one that started in 2011, is one of 4 in phase 4, and was the 8th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

None of the 12 studies in Neuralgia, Postherpetic with a site in United Kingdom is open now. The open studies under Neuralgia, Postherpetic, anywhere →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Neuralgia, Postherpetic with a site in United Kingdom as a file.
02

Study summary

The present study will aim to determine the safety, efficacy, and tolerability of etoricoxib, an NSAID pain reliever, in patients with Neuropathic pain. Neuropathic pain, or pain caused by abnormal activity of sensory neurons, remains undertreated. Post herpetic neuralgia (PHN), which is commonly referred to as post-shingles pain, is the most useful disease to study when investigating the efficacy of pain relievers for Neuropathic pain. Therefore, this study will primarily involve patients with PHN.

The hypothesis in this study is that etoricoxib efficacy is superior to that of placebo.

03

Conditions studied

  • Postherpetic Neuralgia
  • Neuralgia

Keywords

  • Postherpetic neuralgia
  • Neuropathic pain
  • Etoricoxib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be a man or a non-pregnant, non-lactating woman 18 years and older. Women of should be willing to use an acceptable method (at the investigator's discretion) during the study to avoid pregnancy.
  • Have voluntarily provided written .
  • Be able to speak, read, write, and understand English, understand the consent form, complete study related procedures, and communicate with the study staff.
  • Have a clinical diagnosis of PHN by history or objective findings in the opinion of the Investigator for a minimum of 6 months. If the patient pool needs to be expanded to other neuropathic conditions, patients must meet the same criteria of patients with PHN and in addition must have a clinical diagnosis of peripheral diabetic neuropathy (PDN), idiopathic sensory neuropathy (ISN) or small fiber predominant neuropathy (SFN) by history or clinical findings in the opinion of the investigator for a minimum of 6 months.
  • Have a pain intensity score averaging ≥3 on a 0-10 NRS for average daily recall over past 24 hours (at Visit 1)
  • Be, in the opinion of the investigator, in generally good health (other than PHN) at screening, based upon the results of a medical history, physical examination and laboratory analysis

Exclusion criteria

Exclusion Criteria:

  • Are pregnant and/or lactating
  • Have been diagnosed as having any inflammatory arthritis, gout, pseudo-gout, Paget's disease, fibromyalgia or any chronic pain syndrome that in the Investigator's opinion would interfere with the assessment of pain and other symptoms of PHN
  • Have evidence for multiple causes of pain in the neuropathic pain area, such as lumbar radiculopathy in an area of lumbosacral PHN
  • Have any bodily moderate to severe pain (e.g., osteoarthritis) that could confound assessment or self-evaluation of pain due to PHN
  • Use NSAID compounds (oral and topical) within 1 week of study and for the duration of the study
  • Use opioids including tramadol within 1 week of study and for the duration of the study. (Other NP medications are allowed, provided that the doses have been stable for at least one month prior to Visit 1)
  • Have had neuro-ablation or neurosurgical intervention for their PHN
  • Have received nerve block or intrathecal analgesia within 6 weeks of study
  • Have a history of congestive heart failure, unstable coronary artery disease, stroke, or uncontrolled hypertension
  • Have a history of significant gastrointestinal disease, including active gastro-duodenal ulcerations, perforations, or bleeds
  • Have abnormal clinical laboratory test results or vital signs unless deemed not by the investigator
  • Have skin lesions or damage in the area where BSTK measurements are conducted (only applicable to PHN patients)
  • Are undergoing active treatment for cancer, are known to be infected by , or are being acutely and intensively following transplantation
  • Have a history of alcohol or other substance abuse (not including nicotine or tobacco) within five years
  • Known to have a condition that in the investigator's judgment precludes participation in the study
  • Have a significant psychiatric disorder in the opinion of the Investigator.
  • Have received an drug or have used an investigational device in the 30 days prior to study entry
  • Have previously been admitted to this study
  • Are allergic to Arcoxia.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Etoricoxib

    The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib. Patients who experience at least a 30% reduction in pain intensity will be randomized to either continued treatment with etoricoxib 90 mg qd or matching placebo (at a 1:1 ratio) for 4 weeks.

    Drug: Etoricoxib

  • Placebo comparator
    Placebo

    The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib, followed by a 4-week randomized, double-blind, placebo-controlled treatment phase, during which subjects will receive either etoricoxib or placebo.

    Drug: Placebo

Interventions

  • 90mg Tablet QD at 10:00a.m.

    Also known as: Arcoxia

  • DrugPlacebo

    One tablet QD at 10:00a.m.

06

What researchers measure

Primary outcomes

  1. Time to Efficacy Failure

    To compare the efficacy of etoricoxib to placebo in reducing pain intensity in patients with NP, as measured by Time to Efficacy Failure during the Double-Blind Period.

    Time frame: 28 Days

Secondary outcomes

  1. To evaluate the efficacy of etoricoxib in NP during the Open-Label and the Double-Blind Periods

    Time frame: 42 Days

  2. Time to efficacy failure by PHN sub-group based on sensory testing results

    Time frame: 42 Days

  3. Safety as assessed by adverse events, serious adverse events, and vital signs

    Time frame: 56 Days

07

Study locations

2 of 2 sites recruiting
  • MAC (UK) Neruoscience Ltd
    Liverpool, L18 1HQ, United Kingdom
    Recruiting
    • Stuart Ratcliffe, MBChB, MFPM, FRSM · Principal investigator
  • MAC (UK) Neuroscience Ltd
    Manchester, M32 0UT, United Kingdom
    Recruiting
    • Stuart Ratcliffe, MBChB, MFPM, FRSM · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Aug 2011 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2010
First posted
Dec 21, 2010
Start
Mar 2011
Primary completionEst.
Aug 2011
CompletionEst.
Apr 2012
Last update
Mar 23, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01264237
Lead sponsor
Analgesic Solutions
First posted
Dec 21, 2010
Start date
Mar 2011
Primary completion
Aug 2011 (estimated)
Completion
Apr 2012 (estimated)
Last update
Mar 23, 2011

Study contacts

Karen Cowles, RN
Contact
kcowles@analgesicsolutions.com
781-444-9605 ext. 121
Stuart Ratcliffe, MBChB, MFPM, FRSM
principal investigator · MAC (UK) Neuroscience Ltd

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion